Hyperekplexia: Report on phenotype and genotype of 16 Jordanian patients
- 1 April 2017
- journal article
- research article
- Published by Elsevier in Brain and Development
- Vol. 39 (4) , 306-311
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Novel missense mutations in the glycine receptor β subunit gene (GLRB) in startle diseaseNeurobiology of Disease, 2013
- Clonazepam is an effective treatment for hyperekplexia due to a SLC6A5 (GlyT2) mutationMovement Disorders, 2009
- Clinical and Inheritance Profiles of Hyperekplexia in JordanJournal of Child Neurology, 2007
- Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle diseaseNature Genetics, 2006
- Major and minor form of hereditary hyperekplexiaMovement Disorders, 2002
- Evidence for recessive as well as dominant forms of startle disease (hyperekplexia) caused by mutations in the α1 subunit of the inhibitory glycine receptorHuman Molecular Genetics, 1994
- Mutations in the α1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexiaNature Genetics, 1993
- Startle disease, or hyperekplexia: Response to clonazepam and assignment of the gene (STHE) to chromosome 5q by linkage analysisAnnals of Neurology, 1992
- Hyperexplexia or stiff baby syndrome.Archives of Disease in Childhood, 1991
- STARTLE DISEASE OR HYPEREKPLEXIA FURTHER DELINEATION OF THE SYNDROMEBrain, 1980